HealthTree Logo
search more_vert
App Logo
person Sign In / Create Account
Bortezomib Consolidation Is More Effective Than Observation for Newly Diagnosed Multiple Myeloma
Posted: Jul 15, 2015
Bortezomib Consolidation Is More Effective Than Observation for Newly Diagnosed Multiple Myeloma image

Bortezomib-based regimens used in transplantation-ineligible patients with multiple myeloma have shown to produce good outcomes in U.S. community practice, according to a recent study published online this week in the Journal of Clinical Oncology. In the U.S. community-based, three-arm phase IIIB, UPFRONT trial, researchers randomly assigned 502 patients to receive 24 weeks of induction therapy with bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, or bortezomib-melphalan-prednisone. Subsequently, all three groups received additional 25 weeks of bortezomib maintenance therapy. The primary endpoint was progression-free survival, with  overall survival and overall response rate as the secondary endpoints. After median follow-up of 42.7 months, there were no significant differences in progression-free survival or overall survival among the groups. Moreover, bortezomib maintenance therapy did not produce cumulative toxicity. The findings suggest that Bortezomib-based regimens in transplantation-ineligible patients with multiple myeloma produced good outcomes with no particular regimen being better than the other. For the complete article, click here.

The author Lizzy Smith

about the author
Lizzy Smith

Lizzy Smith was diagnosed with myeloma in 2012 at age 44. Within days, she left her job, ended her marriage, moved, and entered treatment. "To the extent I'm able, I want to prove that despite life's biggest challenges, it is possible to survive and come out stronger than ever," she says.

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Janssen Oncology
Adaptive Biotechnologies
Amgen Oncology
Bristol Myers Squibb

Follow Us

facebook instagram twitter youtube